- Home
- REPL vs DGICB Comparison
REPL vs DGICB Comparison
Compare REPL & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- DGICB
- Stock Information
- Founded
- REPL 2015
- DGICB 1986
- Country
- REPL United States
- DGICB United States
- Employees
- REPL N/A
- DGICB N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- REPL Health Care
- DGICB Finance
- Exchange
- REPL Nasdaq
- DGICB Nasdaq
- Market Cap
- REPL 547.0M
- DGICB 562.0M
- IPO Year
- REPL 2018
- DGICB N/A
- Fundamental
- Price
- REPL $5.80
- DGICB $16.60
- Analyst Decision
- REPL Hold
- DGICB
- Analyst Count
- REPL 9
- DGICB 0
- Target Price
- REPL $7.00
- DGICB N/A
- AVG Volume (30 Days)
- REPL 2.5M
- DGICB 614.0
- Earning Date
- REPL 11-11-2025
- DGICB 10-23-2025
- Dividend Yield
- REPL N/A
- DGICB 3.77%
- EPS Growth
- REPL N/A
- DGICB 965.80
- EPS
- REPL N/A
- DGICB 2.34
- Revenue
- REPL N/A
- DGICB $993,644,532.00
- Revenue This Year
- REPL N/A
- DGICB $2.26
- Revenue Next Year
- REPL $408.25
- DGICB $2.96
- P/E Ratio
- REPL N/A
- DGICB $8.27
- Revenue Growth
- REPL N/A
- DGICB 3.36
- 52 Week Low
- REPL $2.68
- DGICB $12.00
- 52 Week High
- REPL $17.00
- DGICB $20.46
- Technical
- Relative Strength Index (RSI)
- REPL 47.90
- DGICB 61.63
- Support Level
- REPL $5.74
- DGICB $14.25
- Resistance Level
- REPL $6.15
- DGICB $16.95
- Average True Range (ATR)
- REPL 0.35
- DGICB 0.11
- MACD
- REPL 0.12
- DGICB 0.30
- Stochastic Oscillator
- REPL 41.03
- DGICB 87.04
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.